qz
Eli Lilly is striking a $1.9 billion gene-editing deal to develop inherited kidney disease treatments

The agreement gives Lilly exclusive rights to Ascidian's RNA exon-editing technology, which repairs faulty genes without altering a patient's DNA [...]

Rating

Innovation

Pricing

Technology

Usability

We have discovered similar tools to what you are looking for. Check out our suggestions for similar AI tools.

Destination
The FDA approves human trials for pig kidney transplants

Despite how it sounds, a xenotransplant isn't something from the latest Alien movie. It's an increasingly credible science: the transplantation of animal organs into humans. The field took o [...]

Match Score: 147.25

Destination
Doctors successfully treated a baby with the first ever personalized gene-editing therapy

A team of doctors and scientists have successfully treated a rare genetic condition with the first-ever personalized gene-editing therapy. Results of the groundbreaking treatment have been published i [...]

Match Score: 142.43

Destination
CRISPR can stop malaria spread by editing a single gene in mosquitos

CRISPR gene-editing therapy has shown great potential to treat and even cure diseases, but scientists are now discovering how it can be used to prevent them as well. A team of researchers found a way [...]

Match Score: 101.71

Destination
Eli Lilly's online health platform just expanded beyond weight loss to tackle Alzheimer’s

Just about a year after launching a direct-to-consumer online platform to sell treatments for diabetes and obesity, Eli Lilly (LLY) is now expanding the program to offer resources for Alzheimer’s d [...]

Match Score: 83.18

Destination
Eli Lilly signs $2.75 billion deal with AI drug developer Insilico Medicine

US pharmaceutical giant Eli Lilly is betting big on AI-driven drug development, signing a $2.75 billion deal with Hong Kong-listed Insilico Medicine.<br /> The article Eli Lilly signs $2.75 bill [...]

Match Score: 78.11

Destination
An Ozempic successor falls short, Eli Lilly's GLP-1 pill, and senators grill RFK: Pharma news roundup

An Eli Lilly exec said the company’s experimental weight-loss pill could make GLP-1 treatments more accessible worldwide, as it would be easier to manufacture and distribute globally. Three U.S. sen [...]

Match Score: 77.17

Destination
Eli Lilly's Zepbound beat Novo Nordisk’s Wegovy in a big weight loss drug study

Eli Lilly’s (LLY) and Novo Nordisk’s (NVO) weight loss drugs went head-to-head in a weight loss study for the first time — and Eli Lilly’s drug came out on top.Read more... [...]

Match Score: 69.61

Destination
Eli Lilly's first weight-loss pill could expand access to GLP-1s around the globe, executive says

Eli Lilly (LLY) believes its experimental weight-loss pill could make GLP-1 treatments more accessible worldwide.Read more... [...]

Match Score: 63.25

Destination
Peter Thiel is utterly wrong about Alzheimer's

The New York Times ran a lengthy interview this morning between columnist Ross Douthat and venture capitalist and PayPal founder Peter Thiel. There's a reason it was published in the opinion sect [...]

Match Score: 60.64